EUVIMEDSkopri EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Peptide‐Drug Conjugates: A New Hope for Cancer

Amy Armstrong iD, Fleur Coburn iD, Yanyamba Nsereko iD, Othman Al Musaimi iD

Journal of Peptide Science · 2025-08 · 31 (8)

DOI: 10.1002/psc.70040 ↗

At a glance

Übersichtsarbeit in Journal of Peptide Science, published online on 2025-07-11. Written by Amy Armstrong and 3 co-authors. Institution: School of Pharmacy, Newcastle University, Newcastle upon Tyne, UK. Major MEDLINE topics: Neoplasms, Peptides, Antineoplastic Agents, Immunoconjugates. Cited 35 times so far (Crossref); 119 references. The full text is freely available (open access, CC BY 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Peptide‐drug conjugates (PDCs) are advancing as targeted cancer therapies, leveraging lessons from antibody‐drug conjugates (ADCs) to improve tumour specificity. These molecules combine a homing peptide with a cytotoxic payload via a linker, enabling precise drug delivery while sparing healthy tissue. Despite their potential, PDCs face challenges including metabolic instability, premature payload release and rapid clearance, limiting clinical success. Only Lutathera remains FDA‐approved after Pepaxto's withdrawal, though Pepaxto retains EMA and MHRA approval—highlighting regulatory and technical complexities. Most PDCs target overexpressed receptors (e.g., somatostatin and GnRH), though novel designs like CBX‐12 employ alternative strategies. Currently, six PDCs are in Phase III trials, with ~96 in development, signalling growing interest. This review explores how ADC research has guided PDC optimisation, particularly in linker chemistry and payload selection. We analyse key structural features governing PDC efficacy, including peptide‐receptor binding and intracellular trafficking. Innovations in stable linkers and tumour‐selective activation mechanisms are critical to overcoming pharmacokinetic hurdles. Promising candidates in late‐stage trials are highlighted, emphasising their potential to address unmet needs in oncology. By refining targeting precision and payload delivery, next‐generation PDCs may expand treatment options for resistant cancers, bridging the gap between biologics and small‐molecule therapies.

Subjects

MeSH terms (MEDLINE)

NeoplasmsPeptidesAntineoplastic AgentsImmunoconjugatesHumansAnimalsDrug Delivery Systems

Author keywords

PDCcancercleavable and noncleavable linkerspeptidesreceptor‐less‐targetingtargeted therapy

Substances

PeptidesAntineoplastic AgentsImmunoconjugates

Authors and institutions

  • School of Pharmacy, Newcastle University, Newcastle upon Tyne, UK.
  • Department of Chemical Engineering, Imperial College London, London, UK.
  • Orthogonal Peptides Limited, London, UK.

ORCID profiles: Amy Armstrong, Fleur Coburn, Yanyamba Nsereko, Othman Al Musaimi

Cite

APA

Armstrong, A., Coburn, F., Nsereko, Y., & Al Musaimi, O. (2025). Peptide‐Drug Conjugates: A New Hope for Cancer. Journal of Peptide Science, 31(8). https://doi.org/10.1002/psc.70040

Vancouver

Armstrong A, Coburn F, Nsereko Y, Al Musaimi O. Peptide‐Drug Conjugates: A New Hope for Cancer. Journal of Peptide Science. 2025;31(8). doi:10.1002/psc.70040

BibTeX
@article{Armstrong2025,
  author = {Armstrong, Amy and Coburn, Fleur and Nsereko, Yanyamba and Al Musaimi, Othman},
  title = {Peptide‐Drug Conjugates: A New Hope for Cancer},
  journal = {Journal of Peptide Science},
  year = {2025},
  volume = {31},
  number = {8},
  doi = {10.1002/psc.70040}
}
Start for free →